Richard S. Geary serves as the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals, Inc., a leading biotechnology company focused on developing RNA-targeted therapies. With over three decades of experience in the pharmaceutical industry, Geary has been instrumental in advancing Ionis' mission to transform the lives of patients with serious diseases. He joined Ionis in 1992 and has since played a pivotal role in the company's growth and success, contributing to the development of numerous innovative therapies. Throughout his career, Geary has demonstrated exceptional leadership and expertise in drug development, particularly in the field of antisense oligonucleotide (ASO) therapeutics. He has been involved in the discovery, development, and clinical advancement of several of Ionis' key programs, including the company's first approved drug, Kynamro, for the treatment of homozygous familial hypercholesterolemia. Geary's scientific contributions have been recognized through numerous publications and patents, cementing his reputation as a thought leader in the industry. As Chief Development Officer, Geary oversees Ionis' drug development strategy, guiding the company's pipeline from early-stage research through to late-stage clinical trials and regulatory approval. His role involves collaborating with cross-functional teams to ensure the successful execution of clinical programs and the advancement of Ionis' novel therapeutic approaches. Geary's strategic vision and deep understanding of the science behind RNA-targeted therapies have been crucial in positioning Ionis as a pioneer in the field, with a robust pipeline of potential treatments for a wide range of diseases.